Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Stock analysts at Cantor Fitzgerald upped their FY2019 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a report issued on Wednesday, November 6th. Cantor Fitzgerald analyst B. Folkes now expects that the specialty pharmaceutical company will earn $14.02 per share for the year, up from their previous forecast of $13.43.
A number of other research analysts have also weighed in on the company. BidaskClub lowered Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 11th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, August 14th. Oppenheimer set a $176.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, September 26th. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, August 12th. Finally, TheStreet lowered Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $167.33.
Shares of NASDAQ:JAZZ traded down $0.44 during midday trading on Friday, reaching $125.52. 5,570 shares of the company’s stock traded hands, compared to its average volume of 468,331. Jazz Pharmaceuticals has a 1 year low of $113.52 and a 1 year high of $154.44. The company has a market cap of $7.24 billion, a P/E ratio of 10.29, a PEG ratio of 1.57 and a beta of 1.09. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.52 and a current ratio of 3.71. The company has a fifty day simple moving average of $124.77 and a two-hundred day simple moving average of $131.70.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.19 by $0.91. Jazz Pharmaceuticals had a return on equity of 28.57% and a net margin of 29.61%. The firm had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. During the same quarter last year, the firm posted $3.58 EPS. The business’s revenue was up 14.6% on a year-over-year basis.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total value of $65,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paul Treacy sold 4,371 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Insiders have sold a total of 5,371 shares of company stock valued at $730,575 over the last three months. Corporate insiders own 4.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its stake in shares of Jazz Pharmaceuticals by 28.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock valued at $364,355,000 after buying an additional 562,700 shares during the period. Nuveen Asset Management LLC lifted its stake in Jazz Pharmaceuticals by 4,979.1% during the second quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock worth $274,324,000 after purchasing an additional 1,886,384 shares during the last quarter. Boston Partners lifted its stake in Jazz Pharmaceuticals by 2.7% during the second quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock worth $191,116,000 after purchasing an additional 35,360 shares during the last quarter. LSV Asset Management lifted its stake in Jazz Pharmaceuticals by 12.5% during the second quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock worth $160,682,000 after purchasing an additional 125,470 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 46.9% during the second quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock worth $147,496,000 after purchasing an additional 337,396 shares during the last quarter. 87.71% of the stock is owned by institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Trading Ex-Dividend Strategy
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.